- Home
- SGMO
as 12-20-2024 2:42pm EST
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 180.5M | IPO Year: | 2000 |
| Target Price: | $7.00 | AVG Volume (30 days): | 7.3M |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.30 - $3.18 | Next Earning Date: | 11-12-2024 |
| Revenue: | $52,291,000 | Revenue Growth: | -74.04% |
| Revenue Growth (this year): | -65.98% | Revenue Growth (next year): | 11.46% |
Latest Sangamo Therapeutics Inc. News
SGMO Breaking Stock News: Dive into SGMO Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
2 days ago
Astellas and Sangamo sign capsid deal for neurological diseases
MT Newswires
3 days ago
Update: Sangamo Grants Capsid License to Astellas for Neurological Disease Targets; Shares Up Pre-Bell
MT Newswires
3 days ago
Sangamo Grants Capsid License to Astellas for Neurological Disease Targets
PR Newswire
3 days ago
Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Business Wire
3 days ago
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
MT Newswires
9 days ago
Truist Upgrades Sangamo Therapeutics to Buy From Hold, Reinstates Price Target at $7
Business Wire
a month ago
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Simply Wall St.
a month ago
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Compare SGMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SGMO Sangamo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.